Kalsiumfolinat Lumacina (Folic Acid)

Folic acid serves as a one‑carbon donor in the tetrahydrofolate cycle, enabling the synthesis of purines, thymidylate, and certain amino acids. These components are essential for DNA replication, repair, and cell division, which underpins its role in correcting folate deficiency and supporting rapidly dividing tissues.

The appropriate dose of Kalsiumfolinat Lumacina is determined by the prescribing healthcare professional based on the patient’s clinical condition, age, weight, and laboratory findings. Dosage regimens are individualized and should follow the prescriber’s instructions.

Folic acid is generally considered safe in pregnancy and is recommended to reduce the risk of neural tube defects. However, specific safety data for Kalsiumfolinat Lumacina during breastfeeding are limited, so use should be guided by a healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Kalsiumfolinat Lumacina is an injectable form of folic acid, offering rapid systemic availability compared with oral tablets or capsules. This can be advantageous in patients with malabsorption, severe deficiency, or when immediate correction is required, whereas oral supplements are typically used for routine maintenance.

The product should be stored at 2‑8 °C, kept refrigerated, protected from light, and must not be frozen or shaken. It should be handled in a clean environment, and any unused portion should be discarded according to local regulations.

Kalsiumfolinat Lumacina is administered by a qualified healthcare professional via intramuscular or intravenous injection, according to the prescriber’s instructions. The route, site, and rate of administration are selected based on the patient’s condition and clinical setting.

Serious risks include severe allergic reactions such as anaphylaxis, rare skin disorders like Stevens‑Johnson syndrome, significant drops in platelet count (thrombocytopenia), and, in very rare cases, seizures. Immediate medical attention is required if any of these events occur.

Individuals with a known hypersensitivity to folic acid or any component of the formulation should avoid using Kalsiumfolinat Lumacina. It should also be used with caution in patients with epilepsy, severe renal impairment, or those receiving drugs that strongly interact with folate metabolism.